By a News Reporter-Staff News Editor at Hematology Week -- Investigators discuss new findings in Cardiovascular Diseases and Conditions. According to news reporting from Herlev, Denmark, by NewsRx journalists, research stated, "Vitamin D has potential antithrombotic effects, suggesting that vitamin D analogs could be used as adjunctive antithrombotic agents. However, epidemiologic evidence of an association between reduced 25-hydroxyvitamin D concentrations and the risk of venous thromboembolism is lacking."
The news correspondents obtained a quote from the research from Copenhagen University Hospital, "To test the hypothesis that reduced plasma 25-hydroxyvitamin D concentrations are associated with an increased risk of venous thromboembolism in the general population. We prospectively studied 18 791 participants from the Copenhagen City Heart Study and the Copenhagen General Population Study. During up to 30 years of follow-up, 950 participants were diagnosed with venous thromboembolism. Plasma 25-hydroxyvitamin D concentrations were adjusted for seasonal variation. The cumulative incidence of venous thromboembolism as a function of age increased with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D (log-rank trend: p=4 x 10(-4) ). On comparison of participants in the lowest and the highest tertile of plasma 25-hydroxyvitamin D concentrations, the crude risk estimate in a model adjusted for age and sex was a 37% (95% confidence interval [CI] 15-64%) increased risk of venous thromboembolism. The corresponding risk increase in a model adjusted for age, sex, body mass index, smoking and cancer was 26% (95% CI 5-51%), and in a multivariable-adjusted model also including physical activity, hormone replacement therapy, menopausal status, oral contraception use and lipid-lowering therapy it was 28% (95% CI 6-53%). Furthermore, corresponding risk increases with attempts to correct for regression dilution bias were 103% (95% CI 37-202%), 70% (95% CI 14-155%) and 73% (95% CI 15-160%) in the three models, respectively."
According to the news reporters, the research concluded: "In these large general population studies, we observed a stepwise increasing risk of venous thromboembolism with decreasing tertiles of seasonally adjusted plasma 25-hydroxyvitamin D concentrations."
For more information on this research see: 25-Hydroxyvitamin D concentrations and risk of venous thromboembolism in the general population with 18,791 participants. Journal of Thrombosis and Haemostasis, 2013;11(3):423-31. (Wiley-Blackwell - www.wiley.com/; Journal of Thrombosis and Haemostasis - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836)
Our news journalists report that additional information may be obtained by contacting P. Brondum-Jacobsen, Dept. of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. Additional authors for this research include M. Benn, A. Tybjaerg-Hansen and B.G Nordestgaard (see also Cardiovascular Diseases and Conditions).
Keywords for this news article include: Herlev, Europe, Denmark, Therapy, Hematology, Risk and Prevention, Venous Thromboembolism, Embolism and Thrombosis, Cardiovascular Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.